Envelope surface glycoprotein gp120
|
env
|
HIV-1 gp120 inhibits CpG-A-induced secretion of IFN-alpha and IFN-beta proteins in PBMCs |
PubMed
|
|
env
|
HIV-1 gp120 modulates expression of the cytokines IL1beta, IL3, IL6, IL10, IL13, IL15, IFNbeta2A, IFNgamma, IFNomega, TNFalpha, VEGF, VEGF B, and LIF in PBMCs and MDMs |
PubMed
|
|
env
|
Sulfate containing galactolipids such as sulfatides on responder cells may be part of the HIV-1 gp120-membrane complex that initiates the induction of interferon (IFN) |
PubMed
|
|
env
|
HIV-1 (possibly through the HIV-1 gp120 protein) induces low levels of IFN-beta in macrophages, and the IFN-beta plays an effective role in restriction of virus replication |
PubMed
|
Envelope transmembrane glycoprotein gp41
|
env
|
IFN-beta inhibits the binding of soluble gp41 to T, B and monocyte cell lines |
PubMed
|
|
env
|
HIV-1 gp41 selectively enhances MHC class I, ICAM-1, IFN-alpha, IFN-beta, and IFN-omega expression in H9 cells |
PubMed
|
Nef
|
nef
|
HIV-1 Nef myristoylation is required for the activation of IRF-3, leading to the synthesis of IFNbeta in monocytes-derived-macrophages |
PubMed
|
|
nef
|
The acidic cluster (residues 64-69) of HIV-1 Nef is required for IRF-3 activation and IFNbeta production |
PubMed
|
Pr55(Gag)
|
gag
|
IFN-beta-induced expression of TRIM22 restricts HIV-1 replication. TRIM22 inhibits the budding of HIV-1 Gag-only particles |
PubMed
|
Tat
|
tat
|
HIV-1 Tat inhibits CpG-A-induced secretion of IFN-alpha and IFN-beta proteins in PBMCs |
PubMed
|
|
tat
|
HIV-1 Tat downregulates the LPS-induction of IFN-beta and concomitantly upregulates IL-6 expression in primary blood monocytes/macrophages |
PubMed
|
|
tat
|
HIV-1 Tat-induced SOCS3 expression inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages in a NF-kappaB-dependent manner |
PubMed
|
|
tat
|
IFN treatment significantly reduces HIV-1 mRNA levels from a Tat defective provirus, suggesting Tat can overcome the inhibitory effects of IFN on HIV-1 replication |
PubMed
|
|
tat
|
IFN beta is an effective inhibitor of HIV-1 Tat-stimulated growth, migration and morphogenesis of an endothelial cell line in vitro and of angiogenesis in vivo |
PubMed
|
|
tat
|
HIV-1 Tat enhances translation of the interferon-inducible enzymes 2-5A synthetase and dsRNA-dependent protein kinase, suggesting interaction of Tat with interferons during HIV-1 replication |
PubMed
|
Vif
|
vif
|
MDDCs treated with HIV-1 DeltaVif mutant induce the expression of IFN-beta gene, suggesting that Vif inhibits IFN-beta induction from cells |
PubMed
|
Vpr
|
vpr
|
MDDCs treated with HIV-1 DeltaVpr mutant induce the expression of IFN-beta gene, suggesting that Vpr inhibits IFN-beta induction from cells |
PubMed
|
Vpu
|
vpu
|
HIV-1 Vpu inhibits IFN-beta promoter activity in an IRF3-independent manner. NF-kappaB-mediated enhancement of the IFN-beta promoter activity is inhibited by HIV-1 Vpu |
PubMed
|
|
vpu
|
Vpu-mediated suppresion of IFNB (IFN-1) production requires engagement and activation of the LILRA4 (ILT7) plasmacytoid dendritic cell receptor by BST2 |
PubMed
|
|
vpu
|
Vpu-mediated modulation of IFNB (IFN-1) production by plasmacytoid dendritric cells requires the presence of BST2 on infected donor cells |
PubMed
|
|
vpu
|
Vpu attenuates IFNB (IFN-1) production upon sensing of HIV-infected cells by plasmacytoid dendritic cells |
PubMed
|
|
vpu
|
Vpu modulates IFNB (IFN-1) production by PBMCs following contact with HIV-infected CD4+ T cells |
PubMed
|
|
vpu
|
IFN-alpha and IFN-beta increase SCYL2 expression and the increase induces PP2A-mediated dephosphorylation of Vpu, suggesting that SCYL2 affects Vpu function through a phosphorylation-dependent mechanism |
PubMed
|
capsid
|
gag
|
Cells treatment with IFN-alpha and IFN-beta inhibit HIV-1 replication with decreased levels of p24 in a dose-dependent manner |
PubMed
|
reverse transcriptase
|
gag-pol
|
The reverse-transcribed viral DNA by HIV-1 RT is the trigger of IRF3 activation and IFN-beta production in HIV-1 infected human monocytic cell line THP1 |
PubMed
|